...
首页> 外文期刊>Journal of biomedical materials research. Part B, Applied biomaterials. >Evaluation of an aqueous drainage glaucoma device constructed of ePTFE.
【24h】

Evaluation of an aqueous drainage glaucoma device constructed of ePTFE.

机译:由ePTFE制成的水性引流性青光眼装置的评估。

获取原文
获取原文并翻译 | 示例
           

摘要

Aqueous drainage devices for the treatment of glaucoma are subject to the same limitations as most polymeric implants, namely a healing response comprised of chronic inflammation and fibrosis. The most widely used devices are currently made of silicone or polypropylene, materials that exhibit biocompatibility difficulties when they are implanted on the sclera underneath the conjunctiva of the eye. Decreased outflow of aqueous fluid to the conjunctival space caused by the development of a fibrous capsule around the device accounts for at least 20% of aqueous shunts failures. Clearly, the need exists to improve the healing response to aqueous drainage devices, and one approach is to develop new polymers or polymer modifications. Improved devices would elicit a limited fibrotic response while increasing neovascularization around the implant. Previous studies have indicated that denucleation markedly improves the healing characteristics and biocompatibility of expanded polytetrafluoroethylene (ePTFE). We reasoned that altering the design of drainage devices to allow the use of denucleated ePTFE in vivo might minimize fibrosis, thereby improving shunt function. We found that after 8 weeks in vivo, experimental shunt function was equivalent to the Baerveldt shunt, while there was less scarring with increased neovascularizatin. These findings suggest that ePTFE has potential as an improved, long-term alternative material for use in constructing glaucoma shunts. Copyright 1999 John Wiley & Sons, Inc.
机译:用于治疗青光眼的水性引流装置与大多数聚合物植入物一样受到相同的限制,即包括慢性炎症和纤维化的愈合反应。目前使用最广泛的设备是由硅树脂或聚丙烯制成的,这些材料植入眼结膜下的巩膜时会表现出生物相容性困难。由装置周围的纤维囊的发展引起的向结膜空间的水性流体流出的减少至少占水性分流器故障的20%。显然,存在改善对排水装置的愈合反应的需要,并且一种方法是开发新的聚合物或聚合物改性剂。改进的装置将引起有限的纤维化反应,同时增加植入物周围的新血管形成。先前的研究表明,去核能显着改善膨胀聚四氟乙烯(ePTFE)的愈合特性和生物相容性。我们认为,改变引流装置的设计以允许在体内使用去核ePTFE可以最大程度地减少纤维化,从而改善分流功能。我们发现,在体内8周后,实验性分流功能与Baerveldt分流功能相当,而随着新血管生成素的增加,瘢痕形成较少。这些发现表明,ePTFE有潜力作为一种改良的长期替代材料,用于构建青光眼分流器。版权所有1999 John Wiley&Sons,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号